Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service

https://doi.org/10.1016/j.ijantimicag.2017.03.016Get rights and content

Highlights

  • This study describes the outpatient parenteral antimicrobial therapy (OPAT) service based in a large UK teaching hospital.

  • Patient acceptance and satisfaction with OPAT were very high.

  • OPAT is safe and clinically efficacious with a low level of complications.

  • OPAT is acceptable for treating a wide range of infections in a complex patient group.

  • OPAT provides substantial cost savings compared with equivalent inpatient care.

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) has evolved relatively slowly in the UK. This study describes the OPAT service based in a large UK teaching hospital in Sheffield, and examines the clinical efficacy, patient acceptability and costs saved over a 10-year period. Data on 3812 episodes of OPAT administered between January 2006 and January 2016 were retrieved from a prospectively maintained electronic database. This study compared the real costs of the OPAT service with estimated costs of conventional inpatient care for these patient episodes, and analysed patient feedback questionnaires that were administered randomly between January 2014 and January 2015. A wide range of infections were managed during the 10-year period. Skin and soft tissue infections accounted for 57% of OPAT episodes. The total number of bed-days saved was 49,854. A successful outcome (cure or improvement) was found in 3357 (88%) episodes. Re-admission occurred in 265 (7%) episodes. The rates of healthcare-associated infections were low: 15 intravenous-line-related infections were recorded (0.3 per 1000 OPAT patient-days). Patient acceptance and satisfaction with OPAT were high. OPAT cost 15%, 39%, 40% and 44% of inpatient costs for an infectious diseases unit, national average costs, other departments (non-infectious diseases unit), and the minimum national average costs for each diagnostic category, respectively. This study shows that OPAT is safe, clinically efficacious and acceptable for treating a wide range of infections with high levels of patient satisfaction and substantial cost savings.

Introduction

Intravenous (IV) antimicrobials are administered increasingly in outpatient settings to treat a wide range of infections in patients who need parenteral therapy, but are well enough not to require hospital admission. Outpatient administration of IV antibiotics was first described in the USA in 1974 for patients with cystic fibrosis [1], and has become widely accepted as the standard of care in many parts of the world for patients with low-risk infections requiring long-term IV antibiotics [2], [3]. In the UK, outpatient parenteral antimicrobial therapy (OPAT) has evolved relatively slowly, but it is now becoming widespread as the benefits to patients and local healthcare systems are being recognized [4].

The Sheffield OPAT service was established in January 2006 and is one of the largest in the UK. Chapman et al reviewed the first 2 years of this service [5]. This study reviews the changes in the OPAT service over the last decade, and examines the clinical efficacy and cost savings from the use of OPAT within the UK National Health Service (NHS).

Section snippets

The OPAT service

The Sheffield OPAT service was established in January 2006, based in a regional infectious diseases unit within a large teaching hospital in South Yorkshire, England. The service grew from a two- to 16-bed (-equivalent) outpatient ‘infusion centre’ in 10 years, and the nursing team increased from 1.4 to 8.6 whole-time equivalents. The service is run by a multi–disciplinary team of infectious diseases physicians, specialist nurses and clerical support staff, with sessional inputs from

Clinical activity

Over the 10-year study period, 3812 OPAT episodes were recorded in 3004 patients. The total number of days of patient care (bed-days saved) delivered through OPAT was 49,854 (range <1 to 533 days; mean 13.1 days). The longest course of treatment was administered to a patient with multi-drug-resistant tuberculosis requiring parenteral capreomycin and meropenem. The number of episodes per year increased from 158 in 2006–2007 to 607 in 2015–2016. The total number of OPAT patient-days also

Discussion

In the UK, OPAT has evolved relatively slowly, but it is now becoming more common as the benefits to patients and local healthcare systems are being recognized [4]. Existing OPAT services have developed uniquely to meet local requirements [6], and have led to variations in practice and model of service delivery. This study reviews the OPAT service based in a regional infectious diseases unit within a large teaching hospital, and adds to the growing evidence that OPAT is safe, effective and

Conclusion

Despite the usual limitations of a retrospective database review with some missing data and potential for bias, as well as the assumptions required for the cost analysis, this large cohort study of 10 years of OPAT experience in Sheffield adds to the growing evidence that administration of IV antimicrobials to patients outside a hospital ward setting is safe, clinically efficacious, and provides substantial cost savings with high levels of patient acceptance and satisfaction. This study found

Acknowledgements

The authors wish to thank Drs Ann Chapman and Ali Omrani who were involved in the early development and growth of the Sheffield OPAT service; the dedicated OPAT specialist nurses; and the Sheffield Infectious Diseases Team.

Funding: None.

Competing interests: The University of Sheffield has received payment from the National Institute for Health and Care Excellence and Novartis for consultancy work completed by Helen Bell.

Ethical approval: Not required.

References (28)

  • M.E. Török et al.

    Outpatient parenteral antimicrobial therapy: recent developments and future prospects

    Curr Opin Investig Drugs

    (2010)
  • A.O. Wai et al.

    Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective

    Pharmacoeconomics

    (2000)
  • D. Nathwani

    The management of skin and soft-tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom

    Chemotherapy

    (2001)
  • L. Bernard et al.

    Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost

    J Clin Pharm Ther

    (2001)
  • Cited by (0)

    View full text